Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Alcon Research, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Alcon Research, LLC

Regulatory records
4
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 4 FDA records to the applicant name Alcon Research, LLC. It includes 2 original PMA approvals. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 2, 2024 to Sep 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LPO appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P220030, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 4 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 20511 Lake Forest Dr., Lake Forest, CA, 92630. Recorded on P230012/S012, decision dated Sep 30, 2026.

Changes described in PMA records

P230012/S012: UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System

FDA recorded a 30-Day Notice decision (OK30) dated 2026-09-30 for P230012/S012, a supplement to the UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The recorded scope covers three manufacturing changes: an alternate supplier for UNIFEYE screen and pad printing operations, an alternate third-party supplier of ink and additive for printed components, and an alternate third-party supplier for machining and passivating the Valve Seat component.

This action concerns the manufacturing supply chain for the delivery system rather than a new approval of the gas or the complete system. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. No supporting documents were included in the source record, so the review basis, any testing performed and whether labeling changed remain unknown.

The OK30 code is reported as recorded; its precise administrative meaning is not defined in the source data and is not interpreted here.

FDA approval-order wording

Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.

Sep 30, 2026 · 30-Day Notice

P220030/S012: UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System

FDA recorded an OK30 decision dated 2026-09-30 for P220030/S012, a 30-Day Notice supplement to the approved application for UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The action covers the recorded manufacturing changes only; it is not a new approval of the gas or the delivery system as a whole.

The recorded changes are three: an alternate supplier for UNIFEYE screen and pad printing operations; an alternate third-party supplier of ink and additive for printed components; and an alternate third-party supplier for machining and passivating the Valve Seat component. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. The source record includes no documents, so the review basis and any supplier qualification details remain unknown.

FDA approval-order wording

Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.

Sep 30, 2026 · 30-Day Notice

P230012: UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy

The FDA approved UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery System on August 26, 2024. Both are indicated for intraocular injection for uncomplicated retinal detachments. The UNIFEYE system lists vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange as associated measures. The UNIPEXY system lists the same associated measures except air/gas exchange.

The applicant is Alcon Research, LLC. The device category is gases used within the eye to place pressure on a detached retina, with product code LPO and specialty ophthalmic. The source statement reports the intended use as submitted; it does not independently establish safety or clinical effectiveness. No supplement type or reason is recorded.

FDA approval-order wording

Approval for UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery System. The UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange.The UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, and laser photocoagulation.

Aug 26, 2024

P220030: UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery

FDA approved UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery System. Both are indicated for intraocular injection for treatment of uncomplicated retinal detachments. The UNIFEYE version lists associated measures including vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange. The UNIPEXY version lists the same associated measures except air/gas exchange.

The device category is gases used within the eye to place pressure on a detached retina. The product code is LPO, specialty Ophthalmic, and applicant Alcon Research, LLC. The decision date is July 2, 2024. The statement reports the approved indication and associated measures but does not provide safety or effectiveness data.

FDA approval-order wording

Approval for UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System and UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery System. The UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, laser photocoagulation, and air/gas exchange.The UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery System is indicated for intraocular injection into the eye for the treatment of uncomplicated retinal detachments. Associated measures used include vitrectomy, fluid/air exchange, transconjunctival and transscleral cryotherapy, and laser photocoagulation.

Jul 2, 2024

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.